Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omilancor in Active Eosinophilic Esophagitis
NCT04835168Phase 1Withdrawn
- Sponsor
- NImmune Biopharma
- Start
- Jan 2022
- Primary completion
- Apr 2022
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of omilancor in eosinophilic esophagitis (EoE) (3 arms), sponsored by NImmune Biopharma. Primary endpoint: Incidence and severity of Adverse Events at 12 Weeks. Planned start Jan 2022; status: withdrawn.
02
Drugs
omilancor
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NCT04835168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04835168.